Jill Shimabuku
Family · Honolulu, HINPI 1811403165
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,115 of the $3,663 with a category attached, or 85.0%. It is spread thinly across 27 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $29.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$571
- Johnson & Johnson$441
- AstraZeneca$420
- Exelixis Inc.$287
- Novartis$265
- Merck$261
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,11585%
- Education$54815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 14 | $571 |
| Johnson & Johnson | 13 | $441 |
| AstraZeneca | 12 | $420 |
| Exelixis Inc. | 5 | $287 |
| Novartis | 13 | $265 |
| Merck | 12 | $261 |
| AbbVie | 14 | $224 |
| Pfizer | 7 | $175 |
| Eisai Inc. | 7 | $162 |
| Incyte Corporation | 2 | $124 |
| Karyopharm Therapeutics Inc. | 3 | $94 |
| Seagen Inc. | 1 | $80 |
| Daiichi Sankyo Inc. | 1 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $60 |
| Beigene USA, Inc. | 2 | $54 |
| Sun Pharmaceutical Industries Inc. | 2 | $50 |
| Boehringer Ingelheim | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Coherus Oncology, Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,663 in reported general payments places this provider in the 90th percentile of 466 family providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 59 | $591 |
| Dexamethasone | 72 | $497 |
| Anastrozole | 16 | $386 |
| Levothyroxine Sodium | 26 | $91 |
| Gabapentin | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other family in Honolulu
- Joey SesonHonolulu$48K
- Kanna DokgoHonolulu$26K
- John MosesHonolulu$24K
- Leif MarzHonolulu$11K
- Ia Lynne AranaHonolulu$9K
- Josette DudoitHonolulu$8K
- Kailie WongHonolulu$6K
- Jane StinsonHonolulu$6K
- Melissa leHonolulu$6K
- Karen RowanHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.